| 2007 |
12/6/07 |
|
FDA Advisory Committee Votes Unanimously to Recommend Approval of Tetrabenazine for Chorea Associated with Huntington Disease |
| |
10/26/07 |
|
Prestwick Announces Peripheral and Central Nervous System Drugs Advisory Committee to Review Tetrabenazine NDA |
| |
8/30/07 |
|
Prestwick Pharmaceuticals, Inc. Continues to Build Management Team with Appointment of Martin Stogniew, PH.D. as Executive Vice President, Chief Technology Officer |
| |
8/23/07 |
|
Prestwick Pharmaceuticals, Inc. Strengthens Management Team with Appointment of Robert S. Radie as Chief Business Officer |
| |
5/3/07 |
|
Clinical Trial Results Suggest Long-Term Treatment Benefit of Tetrabenazine for Chorea Associated with Huntington’s Disease |
|
| 2006 |
8/22/06 |
|
Prestwick Pharmaceuticals Appoints George F. Horner III as President and Chief Executive Officer |
| |
7/24/06 |
|
Prestwick Pharmaceuticals Raises $60 Million in Series C Financing |
| |
3/31/06 |
|
Prestwick Pharmaceuticals Receives FDA Approvable Letter for XENAZINE® (Tetrabenazine) for Treatment of Chorea Associated with Huntington’s Disease |
| |
2/14/06 |
|
Study Published in Neurology Shows Tetrabenazine Significantly Improves Debilitating Movement Disorder Caused by Huntington's Disease |
|
| 2005 |
4/26/05 |
|
Prestwick Pharmaceuticals, Inc. Submits New Drug Application with the FDA to Market Tetrabenazine for the Treatment of Chorea Associated with Huntington’s Disease |
| |
4/15/05 |
|
New Data Reported on Tetrabenazine for the Treatment of Pediatric
Hyperkinetic Movement Disorders |
| |
3/18/05 |
|
Prestwick Pharmaceuticals Launches NITOMAN -Tetrabenazine- Patient
Support Program in Canada; Drug Reimbursement and Pharmacist Support
Services Provided for Eligible Patients |
| |
3/8/05 |
|
New Data Reported on Tetrabenazine in Patients with Movement Disorders
and a History of Depression; Findings Presented at 9th International
Congress of Parkinson's Disease and Movement Disorders |
| |
3/4/05 |
|
VMAT2, a Drug Target
Implicated in Multiple CNS Disorders, is Focus of Scientific Symposium |
|
| 2004 |
12/6/04 |
|
Prestwick Pharmaceuticals Raises $37 Million in Financing |
| |
11/17/04 |
|
William H. Washecka Joins Prestwick Pharmaceuticals as Chief Financial
Officer |
| |
10/21/04 |
|
Christopher O’Brien, MD, Honored
with Guthrie Family Humanitarian Award |
| |
10/3/04 |
|
Tetrabenazine Shown to Significantly Improve Debilitating Movement
Disorder Associated with Huntington's Disease |
| |
9/30/04 |
|
Pivotal Phase III Data of Tetrabenazine for the Treatment of Chorea
Associated with Huntington's Disease to be Presented at American Neurological
Association Annual Meeting |
| |
9/20/04 |
|
Prestwick Pharmaceuticals
Acquires Rights to Commercialize Nitoman™ (tetrabenazine)
in Canada |
| |
9/16/04 |
|
Tetrabenazine
Receives “Fast Track” Designation from
FDA for Chorea Associated with Huntington’s Disease |
| |
3/12/04 |
|
Prestwick Pharmaceuticals Announces the Appointment of Melvin D.
Booth to Board of Directors |
| |
2/18/04 |
|
Prestwick Pharmaceuticals to Present at Smith Barney 4th Annual Specialty
Pharmaceuticals Conference |
|
| 2003 |
12/2/03 |
|
Christopher
O’Brien, MD, Appointed
as Chief Medical Officer |
| |
10/28/03 |
|
Mark Van Ausdal Appointed as General Counsel and Vice President,
Business Development |
| |
10/14/03 |
|
David A. Cory Appointed as Chief Commercial Officer |
| |
9/29/03 |
|
License of Products from Neurobiotec and Schering AG |
| |
6/19/03 |
|
Series A Financing |
